The Incyte Ingenuity Awards in GVHDTM

Supporting the graft-versus-host disease (GVHD) community

The 2026 Incyte Ingenuity Awards in GVHD™ recipients have been selected! Read about the award-winning projects.

Introducing the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute as the Recipients of the 2026 Incyte Ingenuity Awards in GVHD!

We are pleased to announce that the University of Maryland School of Medicine and H. Lee Moffitt Cancer Center & Research Institute are the recipients of the 2026 Incyte Ingenuity Awards in GVHD! These proposals demonstrate a commitment to addressing the specific needs of the GVHD community.

University of Maryland School of Medicine’s logo

The University of Maryland School of Medicine was awarded $100,000 to implement its project, Ocular Surface Imaging Guidance and Health Triage (OSIGHT). The project will develop and pilot an AI-enabled clinical decision support platform to help oncology teams identify patients at risk for ocular GVHD during routine transplant clinic visits. By combining eye imaging, symptom assessments and other clinical indicators, OSIGHT will generate risk classifications and referral recommendations to support earlier detection and intervention. The goal of this project is to expand access to ocular GVHD screening, improve coordination between oncology and ophthalmology teams, and help preserve vision and quality of life for people living with GVHD.

H. Lee Moffitt Cancer Center & Research Institute’s logo

H. Lee Moffitt Cancer Center & Research Institute was awarded $35,000 to implement its project, Understanding the Needs of Caregivers Caring for Those with Chronic GVHD. The project will conduct in-depth interviews with caregivers of adults living with chronic GVHD to better understand their unique challenges, sources of distress and support needs. Findings will be disseminated broadly and inform the future development of tailored supportive care programs designed to improve the wellbeing for GVHD caregivers.

Learn more about the 2026
award-winning projects.

See the Recipients

What Are the Incyte Ingenuity Awards in GVHD?

Watch the following video to hear the inaugural award recipient explain how devastating GVHD can be for patients, and how the Incyte Ingenuity Awards in GVHD program aims to support people living with GVHD, as well as their caregivers and physicians.

Areej E-Jawahri, M.D., Associate Director, Cancer Outcomes Research and Education Program, Director, Bone Marrow Transplant Survivorship Program, Professor of Medicine, Harvard Medical School, provides information on the impact of GVHD and how the Incyte Ingenuity Awards in GVHD aims to support those impacted.

The Incyte Ingenuity Award program is not currently accepting applications.

Applications will reopen in the first half of 2027.

In the meantime, please see below for general program information about the 2027 awards cycle.

Eligibility

Eligibility Information

The following groups and individuals are eligible to apply for the Incyte Ingenuity Awards in GVHD:

Image of hands holding heart

Non-profit 501(c)(3), patient, policy and caregiver organizations

Image of caduceus

Healthcare providers, junior faculty, and/or other clinical and research staff of healthcare organizations*

Image of two people

Individuals or other companies collaborating with these organizations and institutions**

Programs must be independent of any ongoing activities, with the exception of considerably expanding an existing program. Additionally, programs cannot include indirect costs with the proposed budget. To be eligible, you and your organization must be US based (including Washington DC and Puerto Rico).

*Applications must be submitted in the name of an institution, not on behalf of an individual.

**Individuals or other companies interested in applying must partner with either a non-profit organization or a healthcare facility (i.e., hospitals, academic research centers, etc.) to be eligible.

Applications will be disqualified if:

  • Focus is on a particular therapeutic agent, translational research, or clinical research that is interventional in nature
  • Program is based on an existing initiative, with no evidence of ingenuity
  • Organization is improperly identified as a 501(c)(3) organization
  • Application is submitted by a healthcare professional as an individual (individuals will need to partner with a not-for-profit or other organization to be considered)
  • Defined scope does not serve or plan to address a specific need of the GVHD community
  • Request in funding exceeds 25 percent of an organization's overall annual budget and/or includes indirect costs
  • Application is submitted by an employee of Incyte, Real Chemistry, and/or other vendors, or members of the immediate family of any such persons
  • Program is affiliated with Incyte or any of its products or offerings
  • Program is duplicated, with multiple copies of an application submitted by the same organization
  • Program exceeds the maximum application limit per organization (more than five)
  • Program includes monetary support, gifts, or other items of monetary value to patients, either directly or indirectly
  • Applicant and/or organization are not based in the United States

Incyte reserves the right to modify the eligibility requirements at any time.

Have additional questions? Check out our FAQ page.

Peg Squier, Group Vice President, U.S. Medical Affairs, Incyte, provides an overview of the program, outlines eligibility requirements and the necessary steps in submitting an application.

Meet the Judges

Meet the Judges

Meet our 2026 Incyte Ingenuity Awards in GVHD judging panel!

Image of Christina Ferraro

Christina Ferraro, CNP

Christina Ferraro is an accomplished healthcare professional with extensive expertise in hematology and medical oncology. She serves as the Outpatient Advanced Practice Provider Manager at the Cleveland Clinic Cancer Institute, as well as the Director of Survivorship and is a nurse practitioner in the Transplantation and Cellular Therapy and Apheresis programs at the Cleveland Clinic. Prior to her current position, Christina made significant contributions as a nurse and nurse practitioner at the Cleveland Clinic, where she specialized in survivorship, late-effects and graft-versus-host disease in blood and marrow transplant patients. Christina holds a master’s degree in Family Practice Nurse Practitioner from Kent State University and a bachelor’s degree in nursing from The Ohio State University.

More
Less
Image of Hugo Fernandez

Hugo Fernandez, MD

Dr Hugo Fernandez is a hematologist-oncologist, Professor of Oncology at the University of South Florida Morsani College of Medicine and chair and medical director of Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System. His clinical and research efforts focus on molecular therapies for acute myeloid and lymphoid disorders, the development of transplant conditioning regimens for patients with myeloid leukemia and expanding transplantation options for elderly patients. Dr Fernandez received his medical degree from the University of Florida College of Medicine and completed a residency in internal medicine and was chief resident at the University of Miami, Jackson Memorial Medical Center, where he also completed a fellowship in hematology-oncology. Dr Fernandez pursued additional training as an academic fellow in blood and marrow transplantation at the University of Texas, MD Anderson Cancer Center. Prior to being at Moffitt, Dr Fernandez was an associate professor of clinical medicine and director of the bone marrow transplant program at the University of Miami Miller School of Medicine and Sylvester Comprehensive Cancer Center. Dr Fernandez has been published in numerous peer-reviewed journals and is a member of several medical organizations and serves as a board member for the Foundation for the Accreditation of Cell Therapy and for the Moffitt Medical Group. Dr Fernandez is bilingual and speaks English and Spanish.

More
Less
image of Kathleen D. Lyons

Kathleen D. Lyons, ScD, OTR/L

Kathleen D. Lyons, ScD, OTR/L, is an occupational therapist, Professor of Occupational Therapy at the Massachusetts General Hospital (MGH) Institute of Health Professions and currently directs the Cancer Rehabilitation (CaRe) Lab at the MGH Institute focused on helping adult cancer survivors maintain independence and participate in home and community life. Her work integrates occupational therapy theory and implementation science to design and test interventions that reduce disability, improve daily functioning, and promote physical activity among people living with and beyond cancer. Dr Lyons earned her bachelor’s and master’s degrees in occupational therapy from the University of New Hampshire and her Doctor of Science in therapeutic studies from Boston University. She has held research and academic roles at Dartmouth-Hitchcock Medical Center, the Geisel School of Medicine at Dartmouth, Massachusetts General Hospital, and Dana-Farber/Harvard Cancer Center. Dr Lyons has authored over 100 peer-reviewed publications and is nationally recognized for advancing the science of occupational therapy and cancer rehabilitation. She is an inductee of the American Occupational Therapy Foundation’s Academy of Research and received the MGH Institute of Health Profession’s Faculty Award for Excellence in Research in 2024 and the American Congress of Rehabilitation Medicine’s Excellence in Cancer Rehabilitation Award in 2023, reflecting the broad impact of her research on evidence-based cancer rehabilitation practice. Learn more about her award-winning project.

More
Less
Image of Lynne Spina

Lynne Spina

Lynne Spina is the Director of Development and Marketing at BMT InfoNet where she manages corporate partnership programs and brings over two decades of dedication to advancing patient and caregiver advocacy. Deeply empathetic to the caregiver experience, Lynne became involved with BMT InfoNet following her brother’s recovery from a stem cell transplant for acute myeloid leukemia. In addition to leading corporate partnerships, Lynne supports a wide range of patient-focused education and engagement initiatives. Her work includes coordinating BMT InfoNet’s printed patient education materials, collaborating on social media communications, and providing direct support and resources to patients and caregivers navigating transplants and survivorship. She also plays a key role in implementing BMT InfoNet’s annual Survivorship Symposium. Prior to joining BMT InfoNet, Lynne held leadership and marketing communications roles across the healthcare industry, including at ExaroMed Healthcare Consulting, Agfa Corporation and Sandoz Pharmaceuticals. Lynne holds an MBA from Drexel University and a bachelor’s degree in Communications as well as an associate’s degree in Art Advertising from the University of Bridgeport.

More
Less
alert icon

Incyte will not provide any advice or input during the judging process, and all decisions made by the judging panel are made independently and are final. These judges will receive compensation for their services from Incyte, based on fair market value.

Judging Criteria

Judging Criteria

Our independent judging panel will consider the following criteria when evaluating each award application:

Checkmark iconDoes the applicant meet the eligibility requirements?

Handshake iconDid the applicant collaborate with any other organizations to optimize the success of the initiative?

Documents iconDoes the application contain all of the necessary details and supporting documents?

Puzzle piece iconDoes the proposal exhibit a thoughtful, creative and innovative approach to address a specific need within the GVHD community?

Stopwatch iconCan the proposal be completed within the one-year time frame?

Target iconDoes the proposal demonstrate a clear purpose and rationale?

Dollar sign iconDoes the proposal include a realistic and appropriate budget?

Upward pointing arrow iconDoes the proposal have clear and measurable outcomes? Does it follow the SMART (specific, measurable, achievable, realistic, timely) methodology for setting goals?

Incyte reserves the right to change the judging criteria at any time.